AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16277711 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 612
Study 16277711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612
Study 11910270 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline 8 mg
Number of subjects: 16
Study 11910270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11910270 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright artificial light treatment after 2 weeks
Number of subjects: 16
Study 10850749 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline
Number of subjects: 0
Study 10850749 — intervention group
Group type: COMPARATOR
Intervention: Standard care (placebo)
Number of subjects: 0
Study 9010121 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 70
Study 9010121 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 70
Study 1678273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg
Number of subjects: 10
Study 1678273 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 10
Study 1678273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine and Metoclopramide
Number of subjects: 10
Study 6190530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsion intubation
Number of subjects: 106
Study 6190530 — intervention group
Group type: COMPARATOR
Intervention: Retrosternal gastric bypass
Number of subjects: 106
Study 31791299 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the proportion of lower energy options available in targeted food categories (including main meals, snacks, and cold drinks)
Number of subjects: 19
Study 31791299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining increasing the proportion of lower energy options with reducing portion sizes
Number of subjects: 19
Study 30388670 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week foot-ankle muscle strength-training program
Number of subjects: 31
Study 30388670 — intervention group
Group type: COMPARATOR
Intervention: stretching protocol
Number of subjects: 31
Study 26681523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral nerve block
Number of subjects: 16
Study 26681523 — intervention group
Group type: COMPARATOR
Intervention: Nerve-stimulator-guided femoral nerve block
Number of subjects: 16
Study 24831119 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM (cCBT programme)
Number of subjects: 149
Study 24831119 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 149
Study 22748068 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil patient controlled analgesia
Number of subjects: 180000
Study 22748068 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 180000
Study 21273714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral-enriched mouthrinse
Number of subjects: 14
Study 21273714 — intervention group
Group type: COMPARATOR
Intervention: Fluoridated dentifrice
Number of subjects: 14
Study 21273714 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoridated dentifrice
Number of subjects: 14
Study 17919140 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific oral tolerance induction (SOTI)
Number of subjects: 45
Study 17919140 — intervention group
Group type: COMPARATOR
Intervention: Elimination diet (Control)
Number of subjects: 45
Study 16199445 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal education about informed consent (one-hour interactive intervention consisting of a lecture, video, and small-group discussion)
Number of subjects: 27
Study 16199445 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention during the study period)
Number of subjects: 27
Study 12114234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape
Number of subjects: 344
Study 12114234 — intervention group
Group type: COMPARATOR
Intervention: Colposuspension
Number of subjects: 344
Study 10408485 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 203
Study 10408485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 10408485 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 203
Study 8433578 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal and infancy nurse home visitation
Number of subjects: 400
Study 3593481 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol consumption (0.4 g/kg orally)
Number of subjects: 0
Study 3593481 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard (75 g) glucose tolerance test
Number of subjects: 0
Study 3593481 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding or fasting
Number of subjects: 0
Study 29148008 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised forearm exercises 6 weeks pre-operatively
Number of subjects: 40
Study 29148008 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 40
Study 27697397 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 implant‐supported‐overdentures on two tissue‐level implants
Number of subjects: 52
Study 27697397 — intervention group
Group type: COMPARATOR
Intervention: 4 implant‐supported‐overdentures on four tissue‐level implants
Number of subjects: 52
Study 27697397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 24818861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment programme (CONECSI)
Number of subjects: 29
Study 22566279 — intervention group
Group type: EXPERIMENTAL
Intervention: Group acceptance and commitment therapy (ACT) informed stress management intervention
Number of subjects: 56
Study 22566279 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 56
Study 20976813 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ultrasound measurement of bladder wall thickness
Number of subjects: 125
Study 20976813 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound measurement of bladder wall thickness
Number of subjects: 125
Study 20976813 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal ultrasound measurement of bladder wall thickness
Number of subjects: 125
Study 20976813 — intervention group
Group type: COMPARATOR
Intervention: Comparison of abdominal and perineal ultrasound measurements
Number of subjects: 125
Study 18926388 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast stress echocardiography (CSE) with regional diastolic contour abnormalities (RDCAs)
Number of subjects: 106
Study 18926388 — intervention group
Group type: COMPARATOR
Intervention: Contrast stress echocardiography (CSE) without RDCAs
Number of subjects: 106
Study 16485515 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day for 1 year
Number of subjects: 100
Study 16485515 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study 15458147 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeglass displays providing visual stimulation (projecting a feeling of watching a fifty-two-inch television screen)
Number of subjects: 72
Study 15458147 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visual stimulation)
Number of subjects: 72
Study 10534683 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 47
Study 10534683 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 47
Study 9279673 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% ophthalmic solution
Number of subjects: 117
Study 9279673 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 0.03% ophthalmic solution
Number of subjects: 117
Study 9279673 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 1.0% ophthalmic solution
Number of subjects: 117
Study 1702582 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus interferon
Number of subjects: 55
Study 1702582 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a
Number of subjects: 55
Study 1702582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 1702582 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapy
Number of subjects: 55
Study 6853874 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective imagery training group
Number of subjects: 30
Study 6853874 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention group
Number of subjects: 30
Study 6853874 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 31126557 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa (2 gram/day)
Number of subjects: 50
Study 31126557 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch, 2 gram/day)
Number of subjects: 50
Study 27848050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-node-based management (SNBM)
Number of subjects: 1088
Study 27848050 — intervention group
Group type: COMPARATOR
Intervention: Routine axillary clearance (RAC)
Number of subjects: 1088
Study 25899888 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation and stripping (HL + S)
Number of subjects: 100
Study 25899888 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation and endovenous laser ablation (HL + EVLA)
Number of subjects: 100
Study 25899888 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 100
Study 24998653 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg q.d for 1 year)
Number of subjects: 60
Study 24998653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22402864 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 20 mg/kg/day for 12 months
Number of subjects: 64
Study 22402864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22402864 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 64
Study 19901139 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 106
Study 19901139 — intervention group
Group type: COMPARATOR
Intervention: Very low-carbohydrate (LC) diet
Number of subjects: 106
Study 19901139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 106
Study 17973129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast gold partial crowns (CGPC)
Number of subjects: 28
Study 17973129 — intervention group
Group type: COMPARATOR
Intervention: Partial ceramic crowns (PCC)
Number of subjects: 28
Study 15133565 — intervention group
Group type: EXPERIMENTAL
Intervention: First group (open drainage, sealing devitalized material after 1 day)
Number of subjects: 173
Study 15133565 — intervention group
Group type: EXPERIMENTAL
Intervention: Second group (enlarging exposure site, drainage for several minutes, sealing devitalized material)
Number of subjects: 173
Study 15133565 — intervention group
Group type: EXPERIMENTAL
Intervention: Third group (pulpectomy)
Number of subjects: 173
Study 11248182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine therapy (growth factor treatment)
Number of subjects: 54
Study 9794972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pediatric and family support
Number of subjects: 0
Study 9794972 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7660056 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear hearing aid (test HA)
Number of subjects: 32
Study 7660056 — intervention group
Group type: COMPARATOR
Intervention: Linear hearing aid (control HA)
Number of subjects: 32
Study 2402210 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% VO2max exercise for 15 min
Number of subjects: 16
Study 2402210 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% VO2max exercise for 15 min
Number of subjects: 16
Study 2402210 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% VO2max exercise test
Number of subjects: 16
Study 2402210 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 16
Study 7352521 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 137
Study 7352521 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 137
Study 30424684 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity circuit training (HICT)
Number of subjects: 22
Study 30424684 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional progressive resistance training (PRT)
Number of subjects: 22
Study 29084656 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced statin lipid-lowering regimen
Number of subjects: 0
Study 29084656 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 0
Study 26081328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (200-400 mg/day) + Tizanidine (2-4 mg/day) + Anvifen (750 mg/day) for 8 weeks
Number of subjects: 50
Study 26081328 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (200-400 mg/day) + Tizanidine (2-4 mg/day)
Number of subjects: 50
Study 25040039 — intervention group
Group type: EXPERIMENTAL
Intervention: AQX-1125 (450 mg daily)
Number of subjects: 22
Study 22777369 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-releasing vaginal ring
Number of subjects: 65
Study 22777369 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal ring
Number of subjects: 65
Study 22777369 — intervention group
Group type: COMPARATOR
Intervention: Control without vaginal ring
Number of subjects: 65
Study 22777369 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 65
Study 19916252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375% (20 mL)
Number of subjects: 100
Study 19916252 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, 20 mL)
Number of subjects: 100
Study 19916252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375%
Number of subjects: 100
Study 19916252 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 19916252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375% and Placebo
Number of subjects: 100
Study 17924867 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose up to 100 mg three times a day
Number of subjects: 163
Study 17924867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 15030636 — intervention group
Group type: EXPERIMENTAL
Intervention: Brow tension
Number of subjects: 0
Study 15030636 — intervention group
Group type: EXPERIMENTAL
Intervention: Head shaking
Number of subjects: 0
Study 15030636 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal smile
Number of subjects: 0
Study 15030636 — intervention group
Group type: COMPARATOR
Intervention: Cheek tension
Number of subjects: 0
Study 15030636 — intervention group
Group type: COMPARATOR
Intervention: Nodding
Number of subjects: 0
Study 15030636 — intervention group
Group type: COMPARATOR
Intervention: Frown
Number of subjects: 0
Study 11598842 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived HPV-11 L1 VLP vaccine
Number of subjects: 104
Study 9848291 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Number of subjects: 102
Study 9848291 — intervention group
Group type: COMPARATOR
Intervention: Control (no salpingectomy)
Number of subjects: 102
Study 7863149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloidal dressing (HCD)
Number of subjects: 30
Study 7863149 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked gauze
Number of subjects: 30
Study 2846132 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg daily
Number of subjects: 10
Study 2846132 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg daily
Number of subjects: 10
Study 2846132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2846132 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (both doses)
Number of subjects: 10
Study 2846132 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 30844623 — intervention group
Group type: EXPERIMENTAL
Intervention: IATP‐R (Interval aerobic training program with active recovery bouts)
Number of subjects: 60
Study 29189701 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 66
Study 29189701 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing
Number of subjects: 66
Study 25319731 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir-based triple therapy
Number of subjects: 465
Study 23726934 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants experiencing pain and required to reach for the switch that would turn off the experimental stimulus.
Number of subjects: 18
Study 23726934 — intervention group
Group type: COMPARATOR
Intervention: Other 3 conditions (not specified in detail).
Number of subjects: 18
Study 21428465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review
Number of subjects: 118
Study 21428465 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (control)
Number of subjects: 118
Study 19712998 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on device
Number of subjects: 683
Study 19712998 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 683
Study 17509246 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying drugs
Number of subjects: 0
Study 17509246 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment
Number of subjects: 0
Study 17509246 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological markers
Number of subjects: 0
Study 14711840 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg/12 h)
Number of subjects: 202
Study 14711840 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin (400 mg/12 h for three doses then 400 mg/24 h)
Number of subjects: 202
Study 11876465 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed ingestion of caffeine and protein foods and adjustment of the sleep/wake cycle
Number of subjects: 26
Study 11876465 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 9415512 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with chronic low back pain
Number of subjects: 19
Study 9415512 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping constructs
Number of subjects: 19
Study 9415512 — intervention group
Group type: EXPERIMENTAL
Intervention: Self, ideal-self, and social-self constructs
Number of subjects: 19
Study 9415512 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping vs. being pain-free
Number of subjects: 19
Study 8103027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine infusion (up to 600 mg/24 hours)
Number of subjects: 11
Study 2874761 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient arterial occlusion (blood pressure cuffs inflated to 20 to 40 mm Hg above systolic pressure for 20 seconds)
Number of subjects: 60
Study 2874761 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient arterial occlusion
Number of subjects: 60
Study 30595526 — intervention group
Group type: EXPERIMENTAL
Intervention: JR‐141 (iduronate-2-sulfatase fused with anti-human transferrin receptor antibody)
Number of subjects: 14
Study 30595526 — intervention group
Group type: EXPERIMENTAL
Intervention: JR‐141
Number of subjects: 14
Study 29922714 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite pulse technique for arbitrary one-spin rotations and two-spin controlled-not (CNOT) gate.
Number of subjects: 0
Study 29922714 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite pulse technique for two-spin controlled-not (CNOT) gate.
Number of subjects: 0
Study 27422891 — intervention group
Group type: EXPERIMENTAL
Intervention: Toreforant 100 mg/day
Number of subjects: 358
Study 27422891 — intervention group
Group type: COMPARATOR
Intervention: Toreforant 3/10/30 mg
Number of subjects: 358
Study 27422891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 25363176 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with attached stent to Foley catheter (linked stent group)
Number of subjects: 90
Study 25363176 — intervention group
Group type: COMPARATOR
Intervention: Patients with conventional technique (stent separated from Foley) (control group)
Number of subjects: 90
Study 23169286 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing with liquid-based cytology (LBC) triage of hrHPV positives, exit screen at 4 years
Number of subjects: 18648
Study 23169286 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing with LBC triage of hrHPV positives, exit screen at 2 years
Number of subjects: 18648
Study 23169286 — intervention group
Group type: COMPARATOR
Intervention: Liquid based cytology with ASC-US triage and hrHPV testing
Number of subjects: 18648
Study 20307302 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course (7 sessions, median cumulative duration 111 minutes)
Number of subjects: 158
Study 20307302 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium course (12 sessions, median cumulative duration 158 minutes)
Number of subjects: 158
Study 20307302 — intervention group
Group type: EXPERIMENTAL
Intervention: Long course (17 sessions, median cumulative duration 223 minutes)
Number of subjects: 158
Study 18042508 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with 3 agents for 48 weeks
Number of subjects: 1434
Study 18042508 — intervention group
Group type: COMPARATOR
Intervention: Control group (HCV-negative subjects)
Number of subjects: 1434
Study 16146463 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 60
Study 16146463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 60
Study 16146463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12133187 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological-dose steroid therapy for 10 days
Number of subjects: 40
Study 12133187 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for sepsis
Number of subjects: 40
Study 10468081 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial pacing
Number of subjects: 19
Study 10468081 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial pacing
Number of subjects: 19